LACTOLOGY FOUNDATION

A10AB02 — Bovine Insulin (Insulin Beef): Academic Toxicological and Lactological Monograph

1. ATC Classification and Pharmacological Profile

A10AB02 designates insulin (beef), or bovine insulin, within the Anatomical Therapeutic Chemical classification hierarchy A10 (Drugs used in diabetes), A10A (Insulins and analogues), and A10AB (Insulins and analogues for injection, fast-acting). The WHO ATC/DDD system assigns bovine insulin in this category a defined daily dose (DDD) of 40 units by the parenteral route. The DDD is a standardized drug-utilization metric and should not be interpreted as an individualized therapeutic dose. atcddd.fhi.no

Bovine insulin is an animal-derived peptide hormone historically obtained and purified from bovine pancreatic tissue. It consists of two polypeptide chains connected by disulfide bonds and is structurally closely related, but not identical, to human insulin. Differences in several amino-acid residues distinguish bovine from human insulin, while preservation of the principal structural characteristics of the insulin molecule allows effective activation of the human insulin receptor. EMRO Dashboards

Its pharmacodynamic action is fundamentally equivalent to that of endogenous insulin. Binding to the insulin receptor activates receptor tyrosine kinase signaling and downstream metabolic pathways. The resulting effects include increased peripheral glucose uptake, particularly by skeletal muscle and adipose tissue; suppression of hepatic glucose production; inhibition of lipolysis and proteolysis; increased glycogen synthesis; and promotion of anabolic protein and lipid metabolism.

Within A10AB02, bovine insulin is classified according to its fast-acting injectable formulation rather than merely its biological origin. Its clinical effect following subcutaneous administration is therefore intended primarily to provide meal-associated insulin activity. Exact absorption and duration depend on formulation, dose, injection site, local blood flow, physical activity, and individual metabolic factors.

Historically, bovine insulin was an important therapeutic insulin before recombinant human insulin and modern insulin analogues became widely available. Its present clinical relevance is substantially more limited. For example, historical regulatory records document bovine insulin products that have subsequently been withdrawn or discontinued from particular markets. Such market status should not, however, be confused with the pharmacological or lactological properties of the molecule itself. Health Products Canada

A relevant distinction from recombinant human insulin is the greater immunogenic potential of a heterologous animal protein. This feature is important when evaluating adverse reactions in the mother but does not fundamentally alter the expected low systemic exposure of a breastfed infant following ingestion through human milk.

2. Toxicological Profile

The dominant toxicological effect of bovine insulin is excessive insulin activity resulting in hypoglycemia. As with other therapeutic insulins, toxicity is primarily pharmacodynamic rather than the consequence of direct cytotoxic or organ-specific injury.

Hypoglycemia can occur when administered insulin exceeds physiological requirements because of excessive dosing, inadequate carbohydrate intake, delayed or omitted meals, increased physical activity, changes in insulin sensitivity, renal or hepatic dysfunction, intercurrent illness, or errors in insulin administration.

Clinical manifestations range from adrenergic symptoms—including tremor, sweating, palpitations, hunger, and anxiety—to neuroglycopenic manifestations such as weakness, impaired concentration, confusion, behavioral disturbance, visual abnormalities, seizures, loss of consciousness, and coma. Severe or prolonged hypoglycemia may result in permanent neurological injury and can be fatal.

Insulin excess may additionally produce hypokalemia by stimulating cellular uptake of potassium. Clinically important hypokalemia can cause muscle weakness, cardiac electrophysiological abnormalities, arrhythmias, and other complications, particularly following substantial overdose.

Repeated subcutaneous administration may be associated with injection-site reactions and local lipodystrophic changes. Historical animal-derived insulin preparations were also associated with greater immunogenicity than highly purified recombinant human preparations. Formation of anti-insulin antibodies and local or systemic hypersensitivity reactions may therefore be more relevant to bovine insulin than to modern recombinant human insulin. Severe systemic allergic reactions are possible, although their frequency depends substantially on purity and formulation.

In the lactating mother, the most clinically important toxicological issue remains maternal hypoglycemia, particularly during the dynamic postpartum period. Insulin requirements commonly fall after delivery. Current LactMed evidence indicates that women with type 1 diabetes generally require substantially less insulin immediately postpartum than before pregnancy, although individual requirements vary considerably and breastfeeding itself does not necessarily produce a uniform additional reduction in insulin requirements. NCBI

This maternal toxicity has indirect implications for infant safety. Severe hypoglycemia can impair consciousness, coordination, and judgment, temporarily reducing the mother's ability to safely breastfeed, hold, or otherwise care for the infant. Thus, maternal metabolic monitoring is considerably more important clinically than concern about bovine insulin toxicity transmitted through breast milk.

3. Lactation Pharmacology and Breast-Milk Exposure

Direct contemporary pharmacokinetic studies specifically evaluating bovine insulin concentrations in human milk are very limited or unavailable. This evidentiary limitation should be stated explicitly rather than assuming that quantitative data obtained with human insulin or modern analogues are directly interchangeable with bovine insulin.

Nevertheless, the broader lactation pharmacology of insulin provides a strong mechanistic basis for assessment. Insulin is a normal physiological constituent of human breast milk. Current LactMed data document measurable milk insulin concentrations in women without diabetes and increased or exogenous insulin concentrations under certain conditions in insulin-treated mothers. Evidence also suggests that insulin can be actively transported into human milk rather than entering solely through passive paracellular diffusion. NCBI

Historical experiments have directly demonstrated that exogenous animal insulin can appear in breast milk. In one study summarized by LactMed, nursing women received intravenous regular porcine insulin, after which milk insulin concentrations increased, with peak concentrations occurring approximately 30–50 minutes after administration in women with diabetes. Although this observation concerns porcine rather than bovine insulin, it establishes that exogenously administered animal insulin can reach human milk. NCBI

For bovine insulin specifically, some degree of milk transfer is therefore biologically plausible. However, the fundamental determinant of infant safety is not simply whether intact insulin molecules are present in milk, but whether ingested insulin achieves pharmacologically meaningful systemic exposure.

Bovine insulin is a peptide. Following oral ingestion by the breastfed infant, it is subject to proteolytic degradation within the gastrointestinal tract and has extremely poor systemic oral bioavailability. Consequently, even if maternally administered bovine insulin reaches breast milk, the amount ingested does not equate to the infant's systemic dose.

This consideration makes the conventional relative infant dose (RID) less informative than it is for orally bioavailable small-molecule drugs. A calculated milk intake would substantially overestimate biologically active systemic infant exposure if gastrointestinal degradation were ignored.

LactMed's current insulin monograph concludes generally that mothers requiring insulin may breastfeed, that exogenous insulin is excreted into breast milk, and that insulin is itself a normal milk constituent. Direct oral administration of recombinant insulin to premature infants has also been reported as safe, further supporting the low systemic toxicological significance of enteral insulin exposure. NCBI

Nevertheless, because bovine insulin differs structurally from human insulin, evidence concerning recombinant human insulin should be regarded as supportive mechanistic evidence rather than substance-specific pharmacokinetic evidence.

4. Effects in the Breastfed Infant and on Lactation

No well-documented pattern of adverse effects in breastfed infants specifically attributable to maternal therapeutic bovine insulin exposure has been established. Contemporary substance-specific clinical data are sparse, reflecting the historical decline in bovine insulin use rather than evidence of a newly identified lactational hazard.

Clinically significant infant hypoglycemia from exposure through breast milk is not expected. Even if bovine insulin is present in milk, gastrointestinal proteolysis and extremely low oral systemic bioavailability strongly limit the possibility that sufficient biologically active insulin would enter the infant circulation to produce a glucose-lowering effect.

Current LactMed data for insulin overall report no relevant published infant serum concentration information, while supporting breastfeeding in insulin-treated mothers. NCBI

The theoretical immunological implications of orally ingested bovine insulin require more cautious interpretation. Because bovine insulin is a foreign peptide that differs slightly from human insulin, its immunogenic properties following parenteral exposure are greater than those of homologous human insulin. However, this does not establish that the very small amounts potentially encountered through breast milk cause clinically significant sensitization or immune-mediated disease in nursing infants. There is insufficient evidence to identify such an outcome as a clinically established lactational risk.

Insulin itself is a physiological component of breast milk and may exert local biological effects within the developing gastrointestinal tract. LactMed notes potential roles of milk insulin in intestinal maturation and metabolic development. Such observations should not be extrapolated to claim a specific beneficial effect of maternally administered bovine insulin. NCBI

With respect to milk production, adequate maternal insulin activity is physiologically important for normal mammary metabolism and lactogenesis. Current evidence indicates that good maternal glycemic control supports lactational physiology, whereas diabetes and associated metabolic disturbances can contribute to delayed establishment of lactation. NCBI

Therefore, any difficulty in establishing or maintaining lactation in a woman receiving bovine insulin should not automatically be attributed to a direct inhibitory effect of the drug. Underlying diabetes, metabolic control, obstetric factors, postpartum endocrine adaptation, feeding practices, and maternal–infant clinical circumstances should all be considered.

5. Lactological Safety Assessment and Clinical Recommendations

At therapeutic maternal doses, bovine insulin is pharmacologically compatible with breastfeeding on mechanistic and class-based grounds, although the quantity and quality of direct modern lactation data specifically for A10AB02 are limited. Current LactMed guidance supports breastfeeding during insulin therapy generally. NCBI

The assessment rests on several convergent observations: insulin is naturally present in human milk; exogenous insulin can enter breast milk; insulin molecules are peptides susceptible to gastrointestinal degradation; oral systemic bioavailability in the infant is negligible; and clinically meaningful systemic insulin effects from breast-milk exposure have not been established.

Accordingly, maternal bovine insulin therapy alone does not provide a pharmacological reason to interrupt breastfeeding, routinely discard expressed milk, or systematically separate insulin administration from nursing.

Routine measurement of infant blood glucose is likewise not required solely because the mother receives bovine insulin. Investigation is appropriate when clinically indicated—for example, in an infant displaying unexplained lethargy, feeding difficulty, abnormal neurological behavior, or documented metabolic instability—but maternal insulin therapy should not automatically be assumed to be the cause.

The principal clinical focus should remain maternal glycemic control. Insulin requirements should be reassessed after delivery and individualized according to glucose measurements, nutritional intake, activity, breastfeeding pattern, renal function, concurrent disease, and other determinants of insulin sensitivity. Particular attention should be given to prevention of maternal hypoglycemia during periods of changing caloric requirements or feeding schedules. Current LactMed evidence confirms that postpartum insulin requirements frequently differ substantially from those during pregnancy. NCBI

Where bovine insulin is being used because of intolerance, historical treatment continuity, accessibility considerations, or other individualized reasons, lactation alone does not create a pharmacological requirement to change an otherwise effective insulin regimen. Conversely, the limited contemporary availability of bovine insulin and its greater potential for immunogenicity may influence therapeutic selection independently of breastfeeding.

In premature, medically unstable, or metabolically vulnerable infants, individualized clinical observation is reasonable. Such caution reflects the infant's underlying vulnerability and the paucity of bovine-insulin-specific lactation studies rather than evidence demonstrating clinically important toxicity from bovine insulin in human milk.

6. Conclusion

A10AB02 represents fast-acting bovine (beef) insulin, an animal-derived insulin historically used for glycemic control and assigned a parenteral WHO DDD of 40 units. Its metabolic activity is mediated through the insulin receptor and is fundamentally comparable to that of human insulin, although structural differences between bovine and human insulin confer greater potential immunogenicity. atcddd.fhi.no

The principal toxicological hazard is excessive pharmacological activity causing maternal hypoglycemia, with hypokalemia representing an additional concern in substantial overdose. Local injection reactions, lipodystrophy, antibody formation, and hypersensitivity constitute other relevant adverse effects.

Direct quantitative evidence concerning bovine insulin transfer into human milk and outcomes in breastfed infants is limited. Nevertheless, insulin is physiologically present in breast milk, and exogenous insulin—including animal insulin in historical studies—can reach milk. The crucial toxicokinetic consideration is that insulin is a peptide with extremely poor oral systemic bioavailability. Gastrointestinal degradation therefore makes clinically significant systemic exposure of the breastfed infant unlikely. NCBI

No established evidence indicates that maternal therapeutic bovine insulin causes hypoglycemia or other systemic toxicity in breastfed infants. On the basis of insulin pharmacology, historical clinical experience, and current class-level lactation evidence, breastfeeding can generally be continued during maternal A10AB02 therapy.

The major clinical priority during lactation is appropriate maternal insulin adjustment, particularly during the postpartum transition when insulin requirements may change considerably. Thus, the lactological risk assessment of A10AB02 is favorable, while acknowledging that direct contemporary evidence is substantially less extensive than that available for human insulin and modern recombinant insulin analogues. NCBI